tradingkey.logo

BUZZ-Arcus Biosciences falls on pricing $150 mln stock offering at 16% discount

ReutersFeb 18, 2025 12:21 PM

Arcus Biosciences shares RCUS.N drop 4% to $12.57 premarket

Arcus's 13.6 mln stock offering priced at $11 each, a 16% discount to last close

Co plans to use gross proceeds of ~$150 mln to develop its experimental kidney cancer drug and for other purposes

Goldman Sachs, Leerink Partners and Evercore ISI were joint book-runners

Prior to offering, RCUS had 91.5 mln outstanding shares for $1.20 bln market cap, per LSEG data

Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.

Related Articles

KeyAI